Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001443381
Ethics application status
Approved
Date submitted
25/09/2017
Date registered
11/10/2017
Date last updated
21/04/2021
Date data sharing statement initially provided
31/07/2019
Type of registration
Retrospectively registered

Titles & IDs
Public title
Accelerated Theta Burst Transcranial Magnetic Stimulation (TBS) for Depression
Scientific title
Effectiveness of accelerated theta burst transcranial magnetic stimulation for the treatment of depression
Secondary ID [1] 292489 0
None
Universal Trial Number (UTN)
U1111-1199-6602
Trial acronym
TBS for Depression
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Depression 304115 0
Condition category
Condition code
Mental Health 303447 303447 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is a single blind randomised controlled trial investigating whether response to repetitive Transcranial Magnetic Stimulation (rTMS) can be substantially enhanced through the use of an accelerated Theta Burst Stimulation (TBS) treatment protocol. The relative efficacy of standard rTMS and two different strengths of TBS will be compared to explore this, and the most effective TBS treatment parameters.

Participants will be randomly allocated to one of three treatment conditions:
• standard rTMS
• low intensity TBS, or
• high intensity TBS.

All groups will receive 20 active treatments. All participants will take part in interviews at baseline, week 1, 2, 4 and 8-10 weeks. Participants responding to the treatment will be followed up for six months. The participant and the treater will be aware of the treatment condition. The person conducting weekly reviews will be blinded to the participant’s treatment group.

Treatment

Standard rTMS
Participants in standard rTMS will receive one treatment a day for 20 treatment days over 4 weeks. Each treatment session will involve the provision of 75 trains of 10 Hz rTMS to the left dorsolateral prefrontal cortex, in 4 second pulse trains, with 26 second inter-train intervals. Each treatment session will take approximately 37.5 minutes.

TBS treatment
Participants in the TBS groups will receive 11 sessions over 4 days in week 1 (2 sessions on day 1, and 3 sessions each on days 2, 3 and 4), and 9 sessions over 3 days in week 2 (3 sessions per day). Each treatment session will involve 3-pulse 50 Hz bursts applied bilaterally, to the right then left to the dorsolateral prefrontal cortices, at 5 Hz (ie 50 Hz burst of 3 pulses delivered every 200 msec). Right sided cTBS will involve a continuous 600 pulse sequence over 40 seconds. Left sided iTBS will involve a 2-seconds of TBS repeated every 10 seconds (i.e. 2 seconds of TBS followed by an 8 second rest), delivered over 180 seconds. Each TBS treatment session will take approximately 4 minutes. Where multiple sessions are provided in one day, there will be a minimum of 15 minutes break between the treatment sessions.

Both rTMS and TBS treatments involve the application of magnetic stimulation to the dorsolateral prefrontal cortex (DLPFC). During treatment patients will be reclined in a comfortable chair and will be alert and awake. The sensation associated with treatment is usually well tolerated, with most people describing it as a tapping sensation. The treatment intensity for each person for both rTMS and TBS is determined as a percentage of their resting motor threshold (RMT), which is measured by administering single pulse TMS to the motor cortex (area of the brain responsible for muscle control). Standard rTMS treatment will be applied at 120% of the RMT, low intensity TBS at 80% of the RMT, and high intensity TBS at 120% of the RMT. All treatments will be conducted by a qualified TMS nurse. Participants will be monitored at all times, and each treatment time, date and dosage will be logged on a participant's treatment sheet. Intervention adherence and fidelity will be monitored by the TMS accredited nursing staff providing the treatments, and study personnel, including Principal and Associated Investigators, who are trained in the provision and clinical supervision of rTMS/TBS therapy.
Intervention code [1] 298668 0
Treatment: Devices
Comparator / control treatment
The study aim is to investigate whether accelerated TBS is as efficacious as standard daily rTMS, and the most effective TBS treatment parameters. Standard unilateral left high frequency rTMS is the comparator treatment. Low and high intensity TBS will also be compared.
Control group
Active

Outcomes
Primary outcome [1] 302827 0
Quick Inventory of Depressive Symptomatology-Clinician version (QIDS-C)
Timepoint [1] 302827 0
Baseline, week 1, 2, 4 and 8-10. The primary endpoint is at week 4, four weeks after commencement of treatment. Responders (defined as a 50% reduction in total score) will be followed up for six months.
Secondary outcome [1] 337173 0
The rate of change in participants' depressive symptomatology, as measured by reduction in scores on the QIDS-C and SR analysed against the time period across which change occurred.
Timepoint [1] 337173 0
Baseline, week 1, 2, 4 and 8-10.
Secondary outcome [2] 337174 0
Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)
Timepoint [2] 337174 0
Baseline, week 1, 2, 4 and 8-10. Responders (defined as 50% reduction on the QIDS-C from baseline) followed up for six months.
Secondary outcome [3] 337175 0
Scale for Suicidal Ideation
Timepoint [3] 337175 0
Baseline, week 1, 2, 4 and 8-10. Responders (defined as 50% reduction on the QIDS-C from baseline) followed up for six months.
Secondary outcome [4] 337176 0
EuroQol Rating Scale (EQ-5D)
Timepoint [4] 337176 0
Baseline, week 1, 2, 4 and 8-10. Responders (defined as 50% reduction on the QIDS-C from baseline) followed up for six months.

Eligibility
Key inclusion criteria
• Diagnosis of major depressive episode (MDE), in accordance with the Diagnostic
and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context
of unipolar major depressive disorder or bipolar affective disorder.
• 18+ years of age.
• Treatment resistant depression at Stage II of the Thase and Rush classification.
• Quick Inventory of Depressive Symptomatology (QIDS) score of >10 (moderate –
severe depression).
• No increase or initiation of new antidepressant (or other psychoactive) therapy
in the four weeks prior to screening.
• Demonstrated capacity to give informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Inability to provide informed consent
• Medically unstable
• Concomitant neurological disorder or a history of a seizure disorder
• Patients who are pregnant or breastfeeding
• Current Substance or Alcohol dependence

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The treatment group is determined by a computer program that generates random numbers. The researcher with access to this program and who is not involved in patient selection securely provides the treatment group to a member of the treatment team by email or in a sealed envelope. The staff member in receipt of the treatment group is not involved in assessing a patient's eligibility at the baseline assessment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation to one of three treatment conditions will occur via the generation of a single computer number sequence (no stratification).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The primary analysis will take place after all participants, apart from those who may have withdrawn, have had their final assessments. This analysis will be based on the intention-to-treat principle (i.e. subjects will be analysed according to the treatment arm to which they were randomised and the notified stratum to which they belonged at randomisation). A ‘per protocol’ sensitivity analysis will be restricted to participants who did not have a major protocol deviation. Major protocol deviations will be identified prior to database lock.

The primary analysis will compare the proportion of patients who achieve response criteria 4 weeks after commencement of treatment (chi square test) on the QIDS (defined as a 50% reduction in total score).

Following this, a repeated measurements of all the outcome variables will be analysed by fitting linear mixed models using restricted maximum likelihood (REML).

With regard to the secondary hypothesis, to demonstrate non inferiority in the overall efficacy of the accelerated TBS and standard rTMS approaches, we will calculate and report the 90% confidence interval (CI) for the difference between the treatment arms in their mean QIDS levels at week 8. Additional exploratory secondary analyses will be conducted on the secondary measures including suicidality and quality of life using the same mixed model approach.

The projected sample size was based on hypothesised response rates after the initial two weeks of treatment:
- Results from previous studies indicate TBS will induce more rapid treatment
response than standard rTMS.
- At 2 weeks, there will therefore be a greater proportion of treatment responders
in the TBS group than the rTMS group.
- At 4 weeks, we predict a response rate of:
--~45% in the TBS group (expected response rate after a full course of rTMS treatment)
--~20% in the rTMS group (based on previous study response rates)
- Comparing these proportions with a power of 0.9 requires a sample size of 79
per group.
- Recruiting 90 patients per group allows for a 12% drop out rate (typical drop out
rates in our studies are <10%).

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
27/09/2017
Date of last participant enrolment
Anticipated
6/03/2020
Actual
14/01/2021
Date of last data collection
Anticipated
5/10/2020
Actual
14/04/2021
Sample size
Target
300
Accrual to date
Final
300
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 8578 0
Epworth Rehabilitation Camberwell - Camberwell
Recruitment hospital [2] 19168 0
The Adelaide Clinic - Gilberton
Recruitment hospital [3] 19169 0
Gold Coast University Hospital - Southport
Recruitment postcode(s) [1] 16685 0
3124 - Camberwell
Recruitment postcode(s) [2] 33741 0
5081 - Gilberton
Recruitment postcode(s) [3] 33742 0
4215 - Southport

Funding & Sponsors
Funding source category [1] 297057 0
Hospital
Name [1] 297057 0
Epworth HealthCare
Country [1] 297057 0
Australia
Funding source category [2] 308402 0
Charities/Societies/Foundations
Name [2] 308402 0
Blue Sky Foundation
Country [2] 308402 0
Australia
Primary sponsor type
Individual
Name
Professor Paul Fitzgerald
Address
Epworth Camberwell
888 Toorak Road
Camberwell
VICTORIA 3124
Country
Australia
Secondary sponsor category [1] 296066 0
None
Name [1] 296066 0
Address [1] 296066 0
Country [1] 296066 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298241 0
Epworth HealthCare Human Research Ethics Committee
Ethics committee address [1] 298241 0
Ethics committee country [1] 298241 0
Australia
Date submitted for ethics approval [1] 298241 0
19/07/2017
Approval date [1] 298241 0
07/09/2017
Ethics approval number [1] 298241 0
EH2017-255
Ethics committee name [2] 303964 0
Monash Health Human Research Ethics Committee
Ethics committee address [2] 303964 0
Ethics committee country [2] 303964 0
Australia
Date submitted for ethics approval [2] 303964 0
02/07/2019
Approval date [2] 303964 0
11/07/2019
Ethics approval number [2] 303964 0
Res-19-0000-159E

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 76446 0
Prof Paul Fitzgerald
Address 76446 0
Epworth Camberwell
888 Toorak Road
Camberwell VIC 3124
Country 76446 0
Australia
Phone 76446 0
+61 3 9805 4287
Fax 76446 0
Email 76446 0
paul.fitzgerald@monash.edu
Contact person for public queries
Name 76447 0
Leo Chen
Address 76447 0
Epworth Camberwell
888 Toorak Road
Camberwell VIC 3124
Country 76447 0
Australia
Phone 76447 0
+61 3 9809 2444
Fax 76447 0
Email 76447 0
leonard.chen@monash.edu
Contact person for scientific queries
Name 76448 0
Paul Fitzgerald
Address 76448 0
Epworth Camberwell
888 Toorak Road
Camberwell VIC 3124
Country 76448 0
Australia
Phone 76448 0
+61 3 9805 4287
Fax 76448 0
Email 76448 0
paul.fitzgerald@monash.edu

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseDoes switching between high frequency rTMS and theta burst stimulation improve depression outcomes?.2022https://dx.doi.org/10.1016/j.brs.2022.06.005
N.B. These documents automatically identified may not have been verified by the study sponsor.